Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap (Aflibercept) in Myelodysplastic Syndromes
NCT00509249Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2007
- Primary completion
- Dec 2010
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started Sep 2007; status: terminated.
02
Drugs
aflibercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00509249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509249.